Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Jiangsu Hengrui Medicine (China)
Homepage:
hrs.com.cn
Alternate name:
江苏恒瑞医药
ROR:
04ayvvz32
OpenAlex ID:
I4210147685
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2021
·
Huiyan Luo
, Jin Lu
, et al.
·
JAMA
·
805
PDF
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023
·
Shukui Qin
, Shukui Qin
, et al.
·
The Lancet
·
738
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020
·
Shukui Qin
, Zhenggang Ren
, et al.
·
The Lancet Oncology
·
602
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
2020
·
Jing Huang
, Jianming Xu
, et al.
·
The Lancet Oncology
·
591
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
2020
·
Jianming Xu
, Jie Shen
, et al.
·
Clinical Cancer Research
·
565
PDF
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
2018
·
Jianming Xu
, Yun Zhang
, et al.
·
Clinical Cancer Research
·
497
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
2018
·
Wenfeng Fang
, Yunpeng Yang
, et al.
·
The Lancet Oncology
·
489
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
2020
·
Caicun Zhou
, Gongyan Chen
, et al.
·
The Lancet Respiratory Medicine
·
481
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
2021
·
Yunpeng Yang
, Song Qu
, et al.
·
The Lancet Oncology
·
457
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2022
·
Jie Wang
, Caicun Zhou
, et al.
·
The Lancet Oncology
·
421
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
2021
·
Binghe Xu
, Min Yan
, et al.
·
The Lancet Oncology
·
402
Targeted estrogen delivery reverses the metabolic syndrome
2012
·
Brian Finan
, Bin Yang
, et al.
·
Nature Medicine
·
337
Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
2019
·
Fei Ma
, Quchang Ouyang
, et al.
·
Journal of Clinical Oncology
·
334
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
2021
·
Shengxiang Ren
, Jianhua Chen
, et al.
·
Journal of Thoracic Oncology
·
315
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
2020
·
Yi-Zhou Jiang
, Yin Liu
, et al.
·
Cell Research
·
298
PDF
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma
2021
·
Weilin Pu
, Xiao Shi
, et al.
·
Nature Communications
·
263
PDF
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
2024
·
Jianjun Qin
, Liyan Xue
, et al.
·
Nature Medicine
·
255
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
2021
·
Shukui Qin
, Qiu Li
, et al.
·
The Lancet. Gastroenterology & hepatology
·
252
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
2017
·
Xin Li
, Changyong Yang
, et al.
·
European Journal of Pharmaceutical Sciences
·
227
Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
2020
·
Caicun Zhou
, Xingya Li
, et al.
·
Journal of Clinical Oncology
·
205
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
2018
·
Jing Huang
, Binghe Xu
, et al.
·
Clinical Cancer Research
·
203
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
2020
·
Jieqiong Liu
, Qiang Liu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
183
PDF
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
2021
·
Binghe Xu
, Qingyuan Zhang
, et al.
·
Nature Medicine
·
179
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
2021
·
Zhenyu Lin
, Ming Cai
, et al.
·
Journal for ImmunoTherapy of Cancer
·
166
PDF
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
2020
·
Xiaofeng Chen
, Xiaofeng Wu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
163
PDF
Show more works
View as search
Works count:
847
Citation count:
61,560
Year
Topic
Type
